ecancer

Muscle density as a predictive marker for toxicities during ovarian cancer treatment

Dr Lucy Dumas - The Royal Marsden NHS Foundation Trust, London, UK

23 Nov 2018

Using mobile technologies for cervical cancer data collection

Prof David Weller, University of Edinburgh

6 Nov 2018

Comment on 'Ovarian Cancer: An ESMO Guide for Patients'

Dr Nicoletta Colombo - Istituto Europeo di Oncologia, Milan, Italy

1 Nov 2018

Combination strategies of immunotherapy in breast cancer

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

26 Oct 2018

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer

Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA

26 Oct 2018

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah

25 Oct 2018

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

25 Oct 2018

Comment on the Every Woman Study

Clara MacKay - World Ovarian Cancer Coalition, Canada

24 Oct 2018

ESMO 2018: Highlights

Prof Gordon McVie , Will Davies

22 Oct 2018

The past, present and future of treating ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

21 Oct 2018

Comment on SOLO-1 for advanced ovarian cancer

Dr Jonathan Ledermann - University College London, London, UK

21 Oct 2018

Olaparib improves progression free survival up front in ovarian cancer

Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA

21 Oct 2018

More from ecancer